Dendritic cell-based immunotherapy
TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.Abstract:
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.read more
Citations
More filters
Journal ArticleDOI
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
TL;DR: The biological functions of immune cells within TME and their roles in cancer immunotherapy are reviewed, and the perspectives of the basic studies for improving the effectiveness of the clinical use are discussed.
Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TL;DR: A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Journal ArticleDOI
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
TL;DR: It is argued that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
Journal ArticleDOI
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
TL;DR: The role of the different immune landscapes in CRC and their relationships with defined CRC genetic subtypes are discussed and in which ways CRC cells develop mechanisms to resist ICI are considered.
Journal ArticleDOI
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
TL;DR: This review summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS.
References
More filters
Journal ArticleDOI
The role of CD40 and CD154/CD40L in dendritic cells
Daphne Y. Ma,Edward A. Clark +1 more
TL;DR: As research into DC vaccines and immunotherapies progresses, further understanding of CD40 and DC function will advance the applicability of DCs in immunotherapy for human diseases.
Journal ArticleDOI
Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.
TL;DR: Findings on alteration of dendritic cells differentiation, maturation and longevity as a potent mechanism for immune suppression in cancer are examined.
Journal ArticleDOI
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity
Gemma G. Kenter,Marij J. P. Welters,A. Rob P. M. Valentijn,Margriet J. G. Löwik,Dorien M A Berends-van der Meer,Annelies P G Vloon,Jan W. Drijfhout,Amon R. Wafelman,Jaap Oostendorp,Gert Jan Fleuren,Rienk Offringa,Sjoerd H. van der Burg,Cornelis J. M. Melief +12 more
TL;DR: The HPV16 E6 and E7 long peptide-based vaccine is well tolerated and capable of inducing a broad IFNγ-associated T-cell response even in end-stage cervical cancer patients.
Journal ArticleDOI
Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
Jurjen Tel,Erik H.J.G. Aarntzen,Tetsuro Baba,Gerty Schreibelt,Barbara M. Schulte,Daniel Benitez-Ribas,Otto C. Boerman,Sandra Croockewit,Wim J.G. Oyen,Michelle M. van Rossum,Gregor Winkels,Pierre Coulie,Cornelis J. A. Punt,Carl G. Figdor,I. Jolanda M. de Vries +14 more
TL;DR: The results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses.
Journal ArticleDOI
Human tumor antigens for cancer vaccine development.
Rongfu Wang,Steven A. Rosenberg +1 more
TL;DR: The adoptive transfer of tumor‐infiltrating lymphocytes along with interleukin (H.)‐2 into autologous patients with cancer resulted in the objective regression of tumor, indicating that T cells play an important role in tumor regression.
Related Papers (5)
Dendritic cells and the control of immunity
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more